These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38919514)

  • 1. Endoscopic findings and outcomes of gastric mucosal changes relating to potassium-competitive acid blocker and proton pump inhibitor therapy.
    Shinozaki S; Osawa H; Miura Y; Nomoto H; Sakamoto H; Hayashi Y; Yano T; Despott EJ; Yamamoto H
    DEN Open; 2025 Apr; 5(1):e400. PubMed ID: 38919514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of proton pump inhibitors and vonoprazan on the development of 'gastric mucosal redness'.
    Shinozaki S; Osawa H; Miura Y; Hayashi Y; Sakamoto H; Yano T; Kawarai Lefor A; Yamamoto H
    Biomed Rep; 2022 Jun; 16(6):51. PubMed ID: 35620314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
    Akiyama J; Hosaka H; Kuribayashi S; Moriyasu S; Hisada Y; Okubo H; Watanabe K; Imbe K; Nagata N; Kojima Y; Yokoi C; Uemura N; Shimoyama Y; Kawamura O; Yamada M; Kusano M
    Digestion; 2020; 101(2):174-183. PubMed ID: 30897577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term endoscopic change of gastric polyp associated with administration of vonoprazan.
    Ochiai Y; Ito S; Kikuchi D; Hoteya S
    Clin J Gastroenterol; 2024 Aug; 17(4):598-601. PubMed ID: 38575803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of
    Sue S; Maeda S
    Gut Liver; 2021 Nov; 15(6):799-810. PubMed ID: 33850058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton Pump Inhibitor-Related Gastric Mucosal Changes.
    Kim GH
    Gut Liver; 2021 Sep; 15(5):646-652. PubMed ID: 32327613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term changes in serum gastrin levels during standard dose vonoprazan therapy.
    Shinozaki S; Osawa H; Miura Y; Hayashi Y; Sakamoto H; Yano T; Lefor AK; Yamamoto H
    Scand J Gastroenterol; 2022 Dec; 57(12):1412-1416. PubMed ID: 35830502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of
    Kanu JE; Soldera J
    World J Gastroenterol; 2024 Mar; 30(9):1213-1223. PubMed ID: 38577188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis.
    Simadibrata DM; Syam AF; Lee YY
    J Gastroenterol Hepatol; 2022 Dec; 37(12):2217-2228. PubMed ID: 36181401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Ameliorating Effect of Switching to Vonoprazan: A Novel Potassium-Competitive Acid Blocker in Patients with Proton Pump Inhibitor Refractory Non-Erosive Reflux Disease.
    Abe Y; Koike T; Saito M; Okata T; Nakagawa K; Hatta W; Asanuma K; Uno K; Asano N; Imatani A; Masamune A
    Digestion; 2021; 102(3):480-488. PubMed ID: 32062650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Vonoprazan for Refractory Reflux Esophagitis after Esophagectomy.
    Ochiai Y; Iizuka T; Hoshihara Y; Suzuki Y; Hayasaka J; Nomura K; Tanaka M; Odagiri H; Yamashita S; Matsui A; Kikuchi D; Ueno M; Udagawa H; Hoteya S
    Dig Dis; 2021; 39(6):569-576. PubMed ID: 33567428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis.
    Hoshino S; Kawami N; Takenouchi N; Umezawa M; Hanada Y; Hoshikawa Y; Kawagoe T; Sano H; Hoshihara Y; Nomura T; Iwakiri K
    Digestion; 2017; 95(2):156-161. PubMed ID: 28190016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.
    Yamashita H; Kanamori A; Kano C; Hashimura H; Matsumoto K; Tsujimae M; Yoshizaki T; Momose K; Obata D; Eguchi T; Fujita M; Okada A
    Digestion; 2017; 96(1):52-59. PubMed ID: 28662503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potassium-competitive acid blocker-associated gastric mucosal lesions.
    Kubo K; Kimura N; Kato M
    Clin Endosc; 2024 Jul; 57(4):417-423. PubMed ID: 38419167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Vonoprazan in
    Sugimoto M; Yamaoka Y
    Front Pharmacol; 2018; 9():1560. PubMed ID: 30697158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examination on Factors Affecting Symptom Change after Drug Withdrawal in Patients with Mild Erosive Gastroesophageal Reflux Disease Undergoing Symptom-Controlled Maintenance Therapy with Acid-Secretion Inhibition Drugs.
    Tanaka H; Takeuchi T; Nishida S; Hongo H; Takii M; Higashino T; Sanomura M; Miyazaki H; Hoshimoto M; Kimura T; Sakaguchi M; Abe T; Hakoda A; Sugawara N; Iwatsubo T; Kawaguchi S; Ota K; Kojima Y; Higuchi K
    Digestion; 2023; 104(4):270-282. PubMed ID: 36649678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-Analysis.
    Shinozaki S; Kobayashi Y; Osawa H; Sakamoto H; Hayashi Y; Lefor AK; Yamamoto H
    Digestion; 2021; 102(3):319-325. PubMed ID: 31914442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Potential Benefits of Vonoprazan as
    Miftahussurur M; Pratama Putra B; Yamaoka Y
    Pharmaceuticals (Basel); 2020 Sep; 13(10):. PubMed ID: 32998241
    [No Abstract]   [Full Text] [Related]  

  • 19. Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: a prospective study in Japan.
    Hongo M; Fujimoto K;
    J Gastroenterol; 2010 Jun; 45(6):618-24. PubMed ID: 20177714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition.
    Fossmark R; Jianu CS; Martinsen TC; Qvigstad G; Syversen U; Waldum HL
    Scand J Gastroenterol; 2008 Jan; 43(1):20-4. PubMed ID: 18938772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.